Akari Therapeutics plc ADS (AKTX)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the business. Akari Therapeutics is a preclinical oncology company with a staff of five, developing antibody-drug conjugates. Its lead candidate, AKTX-101, is a preclinical trop2-targeting ADC using PH1 payload. That is science, not a commercial enterprise yet: filed figures show no revenue in any period, and the Lynch category is none because the company has lost money in each of the last four years. Net loss was $10.0M in fiscal 2023, $19.8M in fiscal 2024, and $17.3M in fiscal 2025. In the quarter ended March 31, 2026, the net loss was $14.5M, and in the quarter ended June 30, 2026, it was $4.8M. Those are not earnings that support a conventional valuation.

In plain English: Akari Therapeutics is a very small biotech with five employees testing experimental cancer medicines that attach a toxin to an antibody. It has no product sales and keeps losing money—$17.3 million in fiscal 2025—so the business looks weak. At $7.90, the price may look low compared with its stated net assets, but the company burns cash and depends on unproven science.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer